{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:26:40Z","timestamp":1794864400996,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072062"],"award-info":[{"award-number":["82072062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Development Project of Foshan Fourth People\u2019s Hospital","award":["FSSYKF-2020003"],"award-info":[{"award-number":["FSSYKF-2020003"]}],"id":[{"id":"https:\/\/ror.org\/001v2ey71","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Development Project of Foshan Fourth People\u2019s Hospital","award":["FSSYKF-2020017"],"award-info":[{"award-number":["FSSYKF-2020017"]}],"id":[{"id":"https:\/\/ror.org\/001v2ey71","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Department of Science and Technology of Guangdong Province to the Guangdong Provincial Key Laboratory of Biomedical Imaging","award":["2018B030322006"],"award-info":[{"award-number":["2018B030322006"]}],"id":[{"id":"https:\/\/ror.org\/00tjzgn92","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) is a worldwide health threat with high annual morbidity and mortality. Chemotherapeutic drugs such as paclitaxel (PTX) have been widely applied clinically. However, systemic toxicity due to the non-specific circulation of PTX often leads to multi-organ damage, including to the liver and kidney. Thus, it is necessary to develop a novel strategy to enhance the targeted antitumor effects of PTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we engineered exosomes derived from T cells expressing the chimeric antigen receptor (CAR-Exos), which targeted mesothelin (MSLN)-expressing Lewis lung cancer (MSLN-LLC) through the anti-MSLN single-chain variable fragment (scFv) of CAR-Exos. PTX was encapsulated into CAR-Exos (PTX@CAR-Exos) and administered via inhalation to an orthotopic lung cancer mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Inhaled PTX@CAR-Exos accumulated within the tumor area, reduced tumor size, and prolonged survival with little toxicity. In addition, PTX@CAR-Exos reprogrammed the tumor microenvironment and reversed the immunosuppression, which was attributed to infiltrating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and elevated IFN-\u03b3 and TNF-\u03b1 levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provides a nanovesicle-based delivery platform to promote the efficacy of chemotherapeutic drugs with fewer side effects. This novel strategy may ameliorate the present obstacles to the clinical treatment of lung cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-04206-3","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T08:02:23Z","timestamp":1686556943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Wei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanmin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-8390","authenticated-orcid":false,"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"4206_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"4206_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"4206_CR3","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192\u2013237.","journal-title":"Ann Oncol"},{"key":"4206_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263\u20138.","journal-title":"J Clin Oncol"},{"key":"4206_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/277665a0","volume":"277","author":"PB Schiff","year":"1979","unstructured":"Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665\u20137.","journal-title":"Nature"},{"key":"4206_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1158\/1078-0432.CCR-19-2182","volume":"26","author":"DY Zhang","year":"2020","unstructured":"Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C, et al. Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations. Clin Cancer Res. 2020;26:477\u201386.","journal-title":"Clin Cancer Res"},{"key":"4206_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2020.09.004","volume":"495","author":"F Mahmud","year":"2020","unstructured":"Mahmud F, Deng S, Chen H, Miller DD, Li W. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer. Cancer Lett. 2020;495:76\u201388.","journal-title":"Cancer Lett"},{"key":"4206_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367: eaau6977.","journal-title":"Science"},{"key":"4206_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","volume":"21","author":"D Yu","year":"2022","unstructured":"Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, Fang X, Zhang X. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21:56.","journal-title":"Mol Cancer"},{"key":"4206_CR10","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","volume":"10","author":"W Fu","year":"2019","unstructured":"Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, Li T, Shen Y, Fan X, Lin F, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355.","journal-title":"Nat Commun"},{"key":"4206_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, Ruella M, Bhattacharyya S, Wherry EJ, Schuster SJ. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139:1026\u201338.","journal-title":"Blood"},{"key":"4206_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609:369\u201374.","journal-title":"Nature"},{"key":"4206_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"4206_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-022-01671-0","volume":"21","author":"QF Han","year":"2022","unstructured":"Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21:207.","journal-title":"Mol Cancer"},{"key":"4206_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D\u2019Amico TA, et al. Non-small cell lung cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:497\u2013530.","journal-title":"J Natl Compr Canc Netw"},{"key":"4206_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1021\/acs.nanolett.8b03439","volume":"19","author":"R Li","year":"2019","unstructured":"Li R, He Y, Zhu Y, Jiang L, Zhang S, Qin J, Wu Q, Dai W, Shen S, Pang Z, Wang J. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles. Nano Lett. 2019;19:124\u201334.","journal-title":"Nano Lett"},{"key":"4206_CR17","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1021\/acsnano.9b01004","volume":"13","author":"M Riazifar","year":"2019","unstructured":"Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lasser C, Segaliny AI, McIntyre LL, Shelke GV, Hutchins E, Hamamoto A, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano. 2019;13:6670\u201388.","journal-title":"ACS Nano"},{"key":"4206_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41551-022-00902-5","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang Z, Popowski KD, Zhu D, de Juan Abad BL, Wang X, Liu M, Lutz H, De Naeyer N, DeMarco CT, Denny TN, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat Biomed Eng. 2022;6:791\u2013805.","journal-title":"Nat Biomed Eng"},{"key":"4206_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12134","volume":"10","author":"MM Shi","year":"2021","unstructured":"Shi MM, Yang QY, Monsel A, Yan JY, Dai CX, Zhao JY, Shi GC, Zhou M, Zhu XM, Li SK, et al. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracell Vesicles. 2021;10: e12134.","journal-title":"J Extracell Vesicles"},{"key":"4206_CR20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"PC Dinh","year":"2020","unstructured":"Dinh PC, Paudel D, Brochu H, Popowski KD, Gracieux MC, Cores J, Huang K, Hensley MT, Harrell E, Vandergriff AC, et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun. 2020;11:1064.","journal-title":"Nat Commun"},{"key":"4206_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.cell.2022.03.009","volume":"185","author":"C Li","year":"2022","unstructured":"Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X, Song W, Du S, Zhu Y, Huang K, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022;185:1389\u2013401.","journal-title":"Cell"},{"key":"4206_CR22","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.7150\/thno.69533","volume":"12","author":"L Xia","year":"2022","unstructured":"Xia L, Zhang C, Lv N, Liang Z, Ma T, Cheng H, Xia Y, Shi L. AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages. Theranostics. 2022;12:2928\u201347.","journal-title":"Theranostics"},{"key":"4206_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114173","volume":"183","author":"V Forest","year":"2022","unstructured":"Forest V, Pourchez J. Nano-delivery to the lung-by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev. 2022;183: 114173.","journal-title":"Adv Drug Deliv Rev"},{"key":"4206_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vesic.2022.100002","volume":"1","author":"KD Popowski","year":"2022","unstructured":"Popowski KD, Lopez de Juan Abad B, George A, Silkstone D, Belcher E, Chung J, Ghodsi A, Lutz H, Davenport J, Flanagan M, et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracell Vesicle. 2022;1: 100002.","journal-title":"Extracell Vesicle"},{"key":"4206_CR25","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","volume":"5","author":"KD Popowski","year":"2022","unstructured":"Popowski KD, Moatti A, Scull G, Silkstone D, Lutz H, Lopez de Juan Abad B, George A, Belcher E, Zhu D, Mei X, et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter. 2022;5:2960\u201374.","journal-title":"Matter"},{"key":"4206_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2021.11.015","volume":"341","author":"P Kumbhar","year":"2022","unstructured":"Kumbhar P, Manjappa A, Shah R, Jha NK, Singh SK, Dua K, Disouza J, Patravale V. Inhalation delivery of repurposed drugs for lung cancer: approaches, benefits and challenges. J Control Release. 2022;341:1\u201315.","journal-title":"J Control Release"},{"key":"4206_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112\u201320.","journal-title":"Cancer Immunol Res"},{"key":"4206_CR28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41467-022-28251-6","volume":"13","author":"HX Nguyen","year":"2022","unstructured":"Nguyen HX, Wu T, Needs D, Zhang H, Perelli RM, DeLuca S, Yang R, Tian M, Landstrom AP, Henriquez C, Bursac N. Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy. Nat Commun. 2022;13:620.","journal-title":"Nat Commun"},{"key":"4206_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1421","volume":"11","author":"M Dogan","year":"2022","unstructured":"Dogan M, Kozhaya L, Placek L, Karabacak F, Yigit M, Unutmaz D. Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2. Clin Transl Immunol. 2022;11: e1421.","journal-title":"Clin Transl Immunol"},{"key":"4206_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14: eabn2231.","journal-title":"Sci Transl Med"},{"key":"4206_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002737","volume":"9","author":"JT Huckaby","year":"2021","unstructured":"Huckaby JT, Landoni E, Jacobs TM, Savoldo B, Dotti G, Lai SK. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer. 2021;9: e002737.","journal-title":"J Immunother Cancer"},{"key":"4206_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292","volume":"11","author":"KR Michels","year":"2023","unstructured":"Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, Perez AM, Ting HA, Nicolai CJ, Gervascio T, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023;11: e006292.","journal-title":"J Immunother Cancer"},{"key":"4206_CR33","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.","journal-title":"J Extracell Vesicles"},{"key":"4206_CR34","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood-2003-03-0871","volume":"102","author":"A de Gassart","year":"2003","unstructured":"de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood. 2003;102:4336\u201344.","journal-title":"Blood"},{"key":"4206_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ab.2013.12.001","volume":"448","author":"JL Hood","year":"2014","unstructured":"Hood JL, Scott MJ, Wickline SA. Maximizing exosome colloidal stability following electroporation. Anal Biochem. 2014;448:41\u20139.","journal-title":"Anal Biochem"},{"key":"4206_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12951-021-01148-0","volume":"19","author":"T Zhu","year":"2021","unstructured":"Zhu T, Xiao Y, Meng X, Tang L, Li B, Zhao Z, Tan Q, Shan H, Liu L, Huang X. Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. J Nanobiotechnol. 2021;19:391.","journal-title":"J Nanobiotechnol"},{"key":"4206_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12951-021-00907-3","volume":"19","author":"M Wang","year":"2021","unstructured":"Wang M, Lv CY, Li SA, Wang JK, Luo WZ, Zhao PC, Liu XY, Wang ZM, Jiao Y, Sun HW, et al. Near infrared light fluorescence imaging-guided biomimetic nanoparticles of extracellular vesicles deliver indocyanine green and paclitaxel for hyperthermia combined with chemotherapy against glioma. J Nanobiotechnol. 2021;19:210.","journal-title":"J Nanobiotechnol"},{"key":"4206_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41420-021-00791-8","volume":"8","author":"N An","year":"2022","unstructured":"An N, Li Z, Yan X, Zhao H, Yang Y, Liu R, Yang Y, Gao F, Li B, Liu H, Yuan H. Inhibition of Rac1 attenuates radiation-induced lung injury while suppresses lung tumor in mice. Cell Death Discov. 2022;8:26.","journal-title":"Cell Death Discov"},{"key":"4206_CR39","first-page":"457","volume":"74","author":"RM Hoffman","year":"2003","unstructured":"Hoffman RM. Metastatic orthotopic mouse models of lung cancer. Methods Mol Med. 2003;74:457\u201364.","journal-title":"Methods Mol Med"},{"key":"4206_CR40","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3389\/fphar.2019.01333","volume":"10","author":"L Wang","year":"2019","unstructured":"Wang L, Wu W, Zhu X, Ng W, Gong C, Yao C, Ni Z, Yan X, Fang C, Zhu S. The ancient chinese decoction Yu-Ping-Feng suppresses orthotopic lewis lung cancer tumor growth through increasing M1 macrophage polarization and CD4(+) T cell cytotoxicity. Front Pharmacol. 2019;10:1333.","journal-title":"Front Pharmacol"},{"key":"4206_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"4206_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving t cells to solid tumors. Cancer Discov. 2016;6:133\u201346.","journal-title":"Cancer Discov"},{"key":"4206_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003826","volume":"10","author":"T Tokatlian","year":"2022","unstructured":"Tokatlian T, Asuelime GE, Mock JY, DiAndreth B, Sharma S, Toledo Warshaviak D, Daris ME, Bolanos K, Luna BL, Naradikian MS, et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer. 2022;10: e003826.","journal-title":"J Immunother Cancer"},{"key":"4206_CR44","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fphys.2018.01169","volume":"9","author":"G Andriolo","year":"2018","unstructured":"Andriolo G, Provasi E, Lo Cicero V, Brambilla A, Soncin S, Torre T, Milano G, Biemmi V, Vassalli G, Turchetto L, et al. Exosomes from human cardiac progenitor cells for therapeutic applications: development of a GMP-grade manufacturing method. Front Physiol. 2018;9:1169.","journal-title":"Front Physiol"},{"key":"4206_CR45","first-page":"201","volume":"38","author":"R Gallet","year":"2017","unstructured":"Gallet R, Dawkins J, Valle J, Simsolo E, de Couto G, Middleton R, Tseliou E, Luthringer D, Kreke M, Smith RR, et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017;38:201\u201311.","journal-title":"Eur Heart J"},{"key":"4206_CR46","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","volume":"158","author":"D Li","year":"2020","unstructured":"Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology. 2020;158:2250\u201365.","journal-title":"Gastroenterology"},{"key":"4206_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005619","volume":"10","author":"X Kan","year":"2022","unstructured":"Kan X, Zhou G, Zhang F, Ji H, Shin DS, Monsky W, Zheng C, Yang X. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia. J Immunother Cancer. 2022;10: e005619.","journal-title":"J Immunother Cancer"},{"key":"4206_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-021-01406-7","volume":"20","author":"W Jiang","year":"2021","unstructured":"Jiang W, Pan S, Chen X, Wang ZW, Zhu X. The role of lncRNAs and circRNAs in the PD-1\/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 2021;20:116.","journal-title":"Mol Cancer"},{"key":"4206_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86\u2013104.","journal-title":"CA Cancer J Clin"},{"key":"4206_CR50","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.2147\/IJN.S369761","volume":"17","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zeng M, Pi C, Shen H, Yuan J, Zuo Y, Wen J, Guo P, Zhao W, Li K, et al. Novel curcumin derivative-decorated ultralong-circulating paclitaxel nanoparticles: a novel delivery system with superior anticancer efficacy and safety. Int J Nanomed. 2022;17:5265\u201386.","journal-title":"Int J Nanomed"},{"key":"4206_CR51","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jpha.2022.08.002","volume":"12","author":"J Ye","year":"2022","unstructured":"Ye J, Li L, Yin J, Wang H, Li R, Yang Y, Guan Y, Xia X, Liu Y. Tumor-targeting intravenous lipid emulsion of paclitaxel: characteristics, stability, toxicity, and toxicokinetics. J Pharm Anal. 2022;12:901\u201312.","journal-title":"J Pharm Anal"},{"key":"4206_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12951-022-01330-y","volume":"20","author":"J Chen","year":"2022","unstructured":"Chen J, Tan Q, Yang Z, Jin Y. Engineered extracellular vesicles: potentials in cancer combination therapy. J Nanobiotechnol. 2022;20:132.","journal-title":"J Nanobiotechnol"},{"key":"4206_CR53","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.2147\/IJN.S166584","volume":"13","author":"X Wang","year":"2018","unstructured":"Wang X, Chen Q, Zhang X, Ren X, Zhang X, Meng L, Liang H, Sha X, Fang X. Matrix metalloproteinase 2\/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro\/in vivo studies. Int J Nanomed. 2018;13:4641\u201359.","journal-title":"Int J Nanomed"},{"key":"4206_CR54","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2020.02.017","volume":"321","author":"M Huo","year":"2020","unstructured":"Huo M, Wang H, Zhang Y, Cai H, Zhang P, Li L, Zhou J, Yin T. Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation. J Control Release. 2020;321:198\u2013210.","journal-title":"J Control Release"},{"key":"4206_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12225","volume":"42","author":"J Zhang","year":"2022","unstructured":"Zhang J, Pan Y, Shi Q, Zhang G, Jiang L, Dong X, Gu K, Wang H, Zhang X, Yang N, et al. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: a multicenter, randomized, open-label, parallel controlled clinical study. Cancer Commun (Lond). 2022;42:3\u201316.","journal-title":"Cancer Commun (Lond)"},{"key":"4206_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","volume":"15","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15:83.","journal-title":"J Hematol Oncol"},{"key":"4206_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.actbio.2021.09.003","volume":"135","author":"S Hu","year":"2021","unstructured":"Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z, Zhang B, Shi G, Zhang Y, Zhang Y, et al. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021;135:567\u201381.","journal-title":"Acta Biomater"},{"key":"4206_CR58","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146:940\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"4206_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.semcancer.2021.09.004","volume":"86","author":"E Vergani","year":"2022","unstructured":"Vergani E, Daveri E, Vallacchi V, Bergamaschi L, Lalli L, Castelli C, Rodolfo M, Rivoltini L, Huber V. Extracellular vesicles in anti-tumor immunity. Semin Cancer Biol. 2022;86:64\u201379.","journal-title":"Semin Cancer Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04206-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04206-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04206-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T09:05:35Z","timestamp":1686560735000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04206-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4206"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04206-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2494599\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and\/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}